Thiazolidinediones (TZDs) are a multi-effective anti-glycemic drug for type 2 diabetes. Recent clinical trials
suggest TZDs are associated with bone loss or fracture in older diabetic women. Diabetic women exhibit more rapid bone
loss despite the higher baseline bone mineral density. The higher fracture risk of type 2 diabetes may be associated with
neural and vascular complications, or the fragile bone structure.
Statins were found to exert protective effects on bone through their anti-oxidative effect on vascular and advanced glycation
end product-related disorders. The impact of combination use of statins and TZDs on bone however has never been
addressed. Whereas considering the advantages of statins and TZDs in treating type 2 diabetes regarding their cardiovascular
protection and glycemic control improvement, we hypothesize that the concomitant use of statins and TZDs might
also prevent against bone complications of type 2 diabetes or induced by TZDs, especially for older diabetic women.